Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free ENTO Stock Alerts

Entero Therapeutics (ENTO) Competitors

Entero Therapeutics logo
$4.25 -0.30 (-6.59%)
As of 10/14/2026
Compare

ENTO vs. BGDE, TSRI, ARBK, SHPH, and ANY

Should you buy Entero Therapeutics stock or one of its competitors? Entero Therapeutics's main competitors and comparable companies include Big Digital Energy, Inc. Common Stock (BGDE), TSR (TSRI), Argo Blockchain (ARBK), Shuttle Pharmaceuticals (SHPH), and Sphere 3D (ANY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Entero Therapeutics compare to Big Digital Energy, Inc. Common Stock?

Entero Therapeutics (NASDAQ:ENTO) and Big Digital Energy, Inc. Common Stock (NASDAQ:BGDE) are both small-cap technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 6.9% of Big Digital Energy, Inc. Common Stock shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 2.0% of Big Digital Energy, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Entero Therapeutics has a net margin of 0.00% compared to Big Digital Energy, Inc. Common Stock's net margin of -80.68%. Entero Therapeutics' return on equity of -461.02% beat Big Digital Energy, Inc. Common Stock's return on equity.

Company Net Margins Return on Equity Return on Assets
Entero TherapeuticsN/A -461.02% -14.72%
Big Digital Energy, Inc. Common Stock -80.68%-2,070.87%-40.61%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Big Digital Energy, Inc. Common Stock
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

Entero Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Big Digital Energy, Inc. Common Stock has a beta of 4.96, indicating that its share price is 396% more volatile than the broader market.

In the previous week, Big Digital Energy, Inc. Common Stock had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Big Digital Energy, Inc. Common Stock and 1 mentions for Entero Therapeutics. Big Digital Energy, Inc. Common Stock's average media sentiment score of 0.92 beat Entero Therapeutics' score of 0.75 indicating that Big Digital Energy, Inc. Common Stock is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Entero Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Big Digital Energy, Inc. Common Stock
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Entero Therapeutics has higher earnings, but lower revenue than Big Digital Energy, Inc. Common Stock. Entero Therapeutics is trading at a lower price-to-earnings ratio than Big Digital Energy, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A
Big Digital Energy, Inc. Common Stock$39.75M0.75-$23.66M-$12.60N/A

Summary

Big Digital Energy, Inc. Common Stock beats Entero Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Entero Therapeutics compare to TSR?

TSR (NASDAQ:TSRI) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

9.7% of TSR shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 30.2% of TSR shares are owned by insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TSR has a net margin of 2.15% compared to Entero Therapeutics' net margin of 0.00%. TSR's return on equity of 11.21% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TSR2.15% 11.21% 7.97%
Entero Therapeutics N/A -461.02%-14.72%

TSR has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

In the previous week, Entero Therapeutics had 1 more articles in the media than TSR. MarketBeat recorded 1 mentions for Entero Therapeutics and 0 mentions for TSR. Entero Therapeutics' average media sentiment score of 0.75 beat TSR's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
TSR Neutral
Entero Therapeutics Positive

TSR has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than TSR, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TSR$88.82M0.33$1.74M$0.8515.74
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A

Summary

TSR beats Entero Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Entero Therapeutics compare to Argo Blockchain?

Argo Blockchain (NASDAQ:ARBK) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Argo Blockchain
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

2.4% of Argo Blockchain shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Argo Blockchain's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Argo BlockchainN/A N/A N/A
Entero Therapeutics N/A -461.02%-14.72%

Argo Blockchain has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

In the previous week, Argo Blockchain had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Argo Blockchain and 1 mentions for Entero Therapeutics. Argo Blockchain's average media sentiment score of 1.26 beat Entero Therapeutics' score of 0.75 indicating that Argo Blockchain is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Argo Blockchain
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Entero Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Argo Blockchain has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Argo Blockchain, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argo Blockchain$15.52M1.65$5.08M-$117.39N/A
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A

Summary

Argo Blockchain beats Entero Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Entero Therapeutics compare to Shuttle Pharmaceuticals?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shuttle Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 0.4% of Shuttle Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Shuttle Pharmaceuticals has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Shuttle Pharmaceuticals' return on equity of -168.34% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Shuttle PharmaceuticalsN/A -168.34% -90.59%
Entero Therapeutics N/A -461.02%-14.72%

In the previous week, Shuttle Pharmaceuticals and Shuttle Pharmaceuticals both had 1 articles in the media. Shuttle Pharmaceuticals' average media sentiment score of 1.79 beat Entero Therapeutics' score of 0.75 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Shuttle Pharmaceuticals Very Positive
Entero Therapeutics Positive

Entero Therapeutics is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shuttle PharmaceuticalsN/AN/A-$11.72M-$18.64N/A
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A

Summary

Shuttle Pharmaceuticals and Entero Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Entero Therapeutics compare to Sphere 3D?

Sphere 3D (NASDAQ:ANY) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Entero Therapeutics has lower revenue, but higher earnings than Sphere 3D. Entero Therapeutics is trading at a lower price-to-earnings ratio than Sphere 3D, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sphere 3D$11.18M2.24-$21.48M-$3.68N/A
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A

In the previous week, Entero Therapeutics had 1 more articles in the media than Sphere 3D. MarketBeat recorded 1 mentions for Entero Therapeutics and 0 mentions for Sphere 3D. Entero Therapeutics' average media sentiment score of 0.75 beat Sphere 3D's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Sphere 3D Neutral
Entero Therapeutics Positive

Sphere 3D has a beta of 3.32, indicating that its stock price is 232% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Entero Therapeutics has a net margin of 0.00% compared to Sphere 3D's net margin of -332.50%. Sphere 3D's return on equity of -111.12% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sphere 3D-332.50% -111.12% -94.02%
Entero Therapeutics N/A -461.02%-14.72%

17.3% of Sphere 3D shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 6.4% of Sphere 3D shares are owned by insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sphere 3D
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Sphere 3D beats Entero Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENTO vs. The Competition

Export
MetricEntero TherapeuticsSoftware IndustryTechnology SectorNASDAQ Exchange
Market Cap$6.75M$16.67B$29.85B$12.91B
Dividend YieldN/A3.42%2.76%19.59%
P/E Ratio-2.51143.3978.1825.26
Price / SalesN/A1,269.77576.6475.17
Price / CashN/A46.5449.0152.75
Price / Book-1.738.847.696.00
Net Income-$18.06M$429.53M$767.06M$380.56M
7 Day Performance3.16%-0.82%-3.65%-3.34%
1 Month Performance43.10%-0.93%-2.89%-5.89%
1 Year Performance-16.83%-0.01%160.77%-5.56%

Entero Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENTO
Entero Therapeutics
N/A$4.25
-6.6%		N/A-15.7%$6.75MN/AN/A9
BGDE
Big Digital Energy, Inc. Common Stock
1.9016 of 5 stars		$5.14
+1.0%		N/A-75.7%$29.40M$39.75MN/A40
TSRI
TSR
N/A$13.38
flat		N/AN/A$29.04M$88.82M15.74630
ARBK
Argo Blockchain
1.0298 of 5 stars		$2.17
+4.6%		N/A-98.6%$28.92M$15.52MN/A13
SHPH
Shuttle Pharmaceuticals
0.9483 of 5 stars		$5.27
-5.1%		N/A-86.6%$25.07MN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ENTO) was last updated on 10/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
100% overnight gains?
Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...
The Oxford Club | Sponsoredtc pixel